Modular Medical, Inc. (MODD)

The immediate outlook is severely clouded by a relentless downward price trend that has erased over 80% of the company's value over the last three years. While the recent 14-day price action shows a brief, volatile bounce off the lows, the broader context is one of structural failure rather than a temporary dip. The market has punished the stock twice in the last four years, with a massive 70% drop in 2023 followed by another 70% collapse in 2025, leaving the asset in a precarious position where the latest year-on-year performance is still negative. Fundamentally, the business is bleeding cash, reporting significant negative free cash flow and operating cash flow, while earning losses that result in negative earnings per share. This financial distress is compounded by a heavy debt load relative to equity and a lack of any dividend support for shareholders. Although the company is developing medical devices like tubeless pumps, the capital markets have clearly lost faith in the execution or the path to profitability, pricing the stock as a deep value trap rather than a bargain. With no analyst recommendations, a negative forward P/E, and a balance sheet that cannot generate cash to service its obligations or fund growth without dilution, there is no compelling case for a near-term recovery or a long-term turnaround at these levels.